Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Macular Edema Associated With Central Retinal Vein Occlusion in Patients Age 40 Years or Younger
Copyright 2019, SLACK Incorporated.
| Veröffentlicht in: | Ophthalmic surgery, lasers & imaging retina. - 2013. - 50(2019), 4 vom: 01. Apr., Seite e96-e104 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2019
|
| Zugriff auf das übergeordnete Werk: | Ophthalmic surgery, lasers & imaging retina |
| Schlagworte: | Journal Article Angiogenesis Inhibitors Bevacizumab 2S9ZZM9Q9V Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1 |
| Zusammenfassung: | Copyright 2019, SLACK Incorporated. BACKGROUND AND OBJECTIVE: To determine the efficacy of anti-vascular endothelial growth factor (VEGF) therapy for macular edema due to central retinal vein occlusion (CRVO) in younger adults PATIENTS AND METHODS: The outcomes of CRVO patients age 40 years or younger with baseline logarithm of the minimum angle of resolution (logMAR) visual acuity (VA) between 1.30 (20/400 Snellen equivalent) and 0.30 (20/40 Snellen equivalent) and central retinal thickness (CRT) greater than 250 μm were reviewed. VA and CRT were measured at baseline and months 1, 3, 6, and 12 RESULTS: Seventeen eyes of 17 young CRVO patients were included in this study. The logMAR VA improved significantly from 0.64 (20/87 Snellen equivalent) to 0.14 (20/28 Snellen equivalent) 12 months following treatments (P < .001). The CRT decreased from 619 μm ± 238 μm at baseline to 290 μm ± 34 μm at 12 months (P < .001) CONCLUSION: Anti-VEGF injections appear to be effective for macular edema regression and vision improvement in younger adults with CRVO over 12 months of follow-up. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:e96-e104.] |
|---|---|
| Beschreibung: | Date Completed 17.12.2019 Date Revised 17.12.2019 published: Print Citation Status MEDLINE |
| ISSN: | 2325-8179 |
| DOI: | 10.3928/23258160-20190401-13 |